Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.47391/JPMA.20096 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review.
Cureus
September 2024
Department of Medical Education, Nova Southeastern University Dr. Kiran C. Patel College of Allopathic Medicine, Fort Lauderdale, USA.
Polycystic ovarian syndrome (PCOS) impacts the health of women worldwide. It is a condition consisting of dysfunctional cystic ovaries resulting in hormonal imbalance. Many women have symptoms such as infertility, increased production of androgens, and insulin resistance.
View Article and Find Full Text PDFReply to 'fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring careful evaluation of the benefit-risk balance'.
Expert Opin Pharmacother
October 2024
Department of Pharmacy Practice, Auburn University Harrison College of Pharmacy, Auburn, AL, USA.
Pharmacokinetic evaluation of fezolinetant for the treatment of vasomotor symptoms caused by menopause.
Expert Opin Drug Metab Toxicol
October 2024
Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
Article Synopsis
- Vasomotor symptoms (VMS) affect many menopausal women and can negatively impact their quality of life, with available treatments like menopausal hormone therapy (MHT) posing risks for some.
- Fezolinetant is a newly approved oral non-hormonal drug that targets neurokinin 3 receptors to help alleviate moderate to severe VMS and has demonstrated effectiveness in clinical trials.
- The drug appears to improve VMS-related issues such as sleep and overall quality of life while maintaining a safe profile, highlighting its potential as a key option for women unable to use hormone therapy, although further research is needed.
Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance.
Expert Opin Pharmacother
October 2024
Department of Pharmacy, Research Unit in Clinical Pharmacology and Toxicology, Namur Research Institute for Life Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium.
Fezolinetant: A novel NK3R antagonist for treating postmenopausal vasomotor symptoms.
J Pak Med Assoc
August 2024
4th Year MBBS Student, Sindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!